You are here

  • Home
  • Archive
  • Volume 77, Issue 11
  • Anticardiolipin and anti-beta 2 glycoprotein-I antibodies disappearance in patients with systemic lupus erythematosus and antiphospholipid syndrome while on belimumab

Article Text

Article menu
Download PDFPDF
Letter
Anticardiolipin and anti-beta 2 glycoprotein-I antibodies disappearance in patients with systemic lupus erythematosus and antiphospholipid syndrome while on belimumab
  1. Savino Sciascia,
  2. Elena Rubini,
  3. Massimo Radin,
  4. Irene Cecchi,
  5. Daniela Rossi,
  6. Dario Roccatello
  1. Center of Research of Immunopathology and Rare Diseases-Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, S. Giovanni Bosco Hospital, University of Turin, Turin, Italy
  1. Correspondence to Dr Savino Sciascia, Center of Research of Immunopathology and Rare Diseases-Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, S. Giovanni Bosco Hospital, University of Turin, Turin 10154, Italy; savino.sciascia{at}unito.it

https://doi.org/10.1136/annrheumdis-2018-213496

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    The current management of antiphospholipid syndrome (APS) centres on attenuating the procoagulant state while balancing the haemorrhagic risks.1 This approach relies mainly on a thromboprophylaxis strategy rather than targeting pathogenic antiphospholipid antibodies (aPL)-mediated pathways.

    Herewith, we report the aPL disappearance in three patients with APS associated to systemic lupus erythematous (SLE) while on treatment with belimumab, potentially paving the way for development of new targeted therapies for APS. Belimumab is a monoclonal antibody that works by blocking the B-lymphocyte stimulator and avoiding B-cell activation.2 It is the first biological drug approved for the treatment of autoantibody positive SLE in active phase and it has shown its capability to reduce the antibodies levels, including anti-double stranded-DNA.3 Intriguingly, in murine models of APS in the setting of SLE, belimumab …

    View Full Text

    Footnotes

    • SS and ER contributed equally.

    • Handling editor Josef S Smolen

    • Contributors ER and SS designed the study, performed data analysis and drafted the manuscript. ER, IC, DR1, MR, DR2 and SS gave a substantial contribution to concept and study design and participated in the interpretation of data. All the authors gave the final approval of the version to be published.

    • Competing interests None declared.

    • Patient consent Not required.

    • Provenance and peer review Not commissioned; externally peer reviewed.